Lavipharm

Lavipharm EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Lavipharm (LAVI.AT) as of Oct 24, 2026 is 6.92 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 4.36 % — a change of 58.55% (higher).

EBIT/Assets

6.92 %

YoY

58.55%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Lavipharm is 2025 6.92 % . Operating Income to Assets Ratio (EBIT/Assets) of Lavipharm was 2024 4.36 % . It decreases by 58.55% higher compared to the previous year.

The Lavipharm EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
11.97 EUR
Jan 1, 2019
8.14 EUR
Jan 1, 2020
10.42 EUR
Jan 1, 2021
10.20 EUR
Jan 1, 2022
3.37 EUR
Jan 1, 2023
4.00 EUR
Jan 1, 2024
4.36 EUR
Jan 1, 2025
6.92 EUR
The Lavipharm EBIT/Assets history
YEAREBIT/AssetsYoY
6.92 %+58.55%
4.36 %+9.04%
4.00 %+18.82%
3.37 %-67.01%
10.20 %-2.02%
10.42 %+27.98%
8.14 %-32.04%
11.97 %-63.25%
32.58 %+277.32%
8.63 %-494.31%
-2.19 %-87.18%
-17.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

Operating Income to Assets Ratio (EBIT/Assets) of Lavipharm is 6.92 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Lavipharm changed from 4.36 % to 6.92 %, representing a 58.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Lavipharm since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Lavipharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lavipharm

All Key Metrics — Lavipharm